Updated: US intelligence officials told Congress that WuXi transferred IP to Chinese authorities — report

Max Gelman

Senior Editor

WuXi AppTec reportedly transferred a US client’s intellectual property to Chinese authorities, American intelligence officials told Congress in February.

According to a Reuters

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: US intelligence officials told Congress that WuXi transferred IP to Chinese authorities — report

Max Gelman

Senior Editor

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

Up­dat­ed: US in­tel­li­gence of­fi­cials told Con­gress that WuXi trans­ferred IP to Chi­nese au­thor­i­ties — re­port

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Updated: US intelligence officials told Congress that WuXi transferred IP to Chinese authorities — report

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena